What Are SGLT2 Inhibitors?
Steglatro (ertugliflozin) and Jardiance (empagliflozin) are part of a class of prescription medications called sodium-glucose cotransporter 2 (SGLT2) inhibitors. These oral tablets are used to help manage blood sugar levels in adults with type 2 diabetes, typically alongside a healthy diet and regular exercise. The core function of these medications is to target the SGLT2 protein in the kidneys. This protein is responsible for reabsorbing glucose from the urine back into the bloodstream. By blocking its action, SGLT2 inhibitors cause the kidneys to excrete excess glucose through the urine, thereby lowering blood glucose concentrations. This mechanism of action, while similar for both drugs, does not make them identical, and their specific indications and clinical profiles have notable distinctions.
The Core Difference: Active Ingredients
The most fundamental reason that Steglatro and Jardiance are not the same is their different active ingredients. Steglatro contains ertugliflozin, while Jardiance contains empagliflozin. While both chemical compounds fall under the same SGLT2 inhibitor category, they are distinct molecules. This difference in molecular structure contributes to variations in their efficacy profiles, approved uses, and potentially their side effect landscape, although many common side effects are shared due to their similar mechanism of action.
Expanding Beyond Blood Sugar Control: Approved Uses
For a long time, the primary function of SGLT2 inhibitors was solely for glycemic control in type 2 diabetes. However, clinical research has revealed significant cardiovascular and renal benefits associated with some medications in this class. Here, Jardiance has a distinct advantage over Steglatro due to its broader FDA-approved indications. Jardiance is approved to reduce the risk of cardiovascular death, hospitalization for heart failure, and the worsening of kidney problems in certain adults. Steglatro, on the other hand, is currently only approved for the treatment of type 2 diabetes in adults. This difference is a key factor for healthcare providers when determining the most appropriate treatment, especially for patients with a history of cardiovascular disease or chronic kidney disease.
A Head-to-Head Comparison: Jardiance vs. Steglatro
To highlight the key differences between these two medications, the following table provides a detailed comparison.
| Feature | Jardiance (Empagliflozin) | Steglatro (Ertugliflozin) |
|---|---|---|
| Active Ingredient | Empagliflozin | Ertugliflozin |
| Drug Class | SGLT2 inhibitor | SGLT2 inhibitor |
| Primary Indication | Type 2 diabetes | Type 2 diabetes |
| Additional Indications | Reduce risk of CV death, hospitalization for heart failure, and worsening of chronic kidney disease | None (currently limited to Type 2 diabetes) |
| Dosage | 10 mg or 25 mg once daily | 5 mg or 15 mg once daily |
| Approved Age | Adults and pediatric patients (10 years and older) with Type 2 diabetes | Adults only |
| Generic Availability | No (as of late 2023) | No (as of summer 2025) |
| Major Clinical Evidence | Strong evidence for CV and renal benefits (e.g., EMPA-REG OUTCOME trial) | Efficacy in lowering HbA1c and weight reduction |
Potential Side Effects and Risks
Because they operate in a similar manner, many of the potential side effects for Jardiance and Steglatro overlap. The most commonly reported side effects include urinary tract infections and genital yeast infections, which are caused by the increased glucose in the urine. Other shared risks include dehydration, low blood pressure (especially for patients also taking diuretics), and dizziness. Both drugs also carry a rare but serious risk of diabetic ketoacidosis (DKA), a medical emergency. It is crucial for patients to stay well-hydrated and monitor for symptoms. Rare but severe infections, such as Fournier's gangrene, have also been associated with SGLT2 inhibitors. Patients should always discuss their medical history and all current medications with a healthcare provider to understand their personal risk profile.
Dosage and Cost Considerations
Dosage differs between the two drugs, with Jardiance available in 10 mg and 25 mg tablets and Steglatro in 5 mg and 15 mg tablets. The appropriate dose is determined by a healthcare provider based on the patient's individual needs and response to treatment. As of recent data, neither medication is available as a generic, meaning costs can be significant, especially without insurance. Pricing varies by pharmacy and insurance plan, but discounts and patient assistance programs are often available to help offset the cost. Some sources note that Steglatro may have a lower cash price than Jardiance, but daily costs can be comparable depending on the dosage.
Conclusion: The Right Choice Is Personalized
In summary, the notion that is Steglatro the same as Jardiance is a misconception. While they share a drug class and a basic mechanism for lowering blood sugar, they are not interchangeable. Their primary differences lie in their active ingredients, the broader FDA-approved indications for Jardiance covering cardiovascular and kidney benefits, and their specific dosage strengths. The choice between Jardiance and Steglatro should be based on a comprehensive assessment of a patient's overall health, including their risk factors for heart and kidney disease, and should always be made in consultation with a qualified healthcare provider. For a detailed, side-by-side comparison of specific features, you can consult reliable drug information resources.
